Like this article?
Get your free daily medical news from Physician's First Watch.
FDA Approves Degarelix for Advanced Prostate Cancer
The FDA has announced the approval of what it calls the "first new drug in several years" for the treatment of advanced prostate cancer.
The agency says that degarelix, a gonadotropin-releasing-hormone receptor inhibitor, does not cause an initial promotion of tumor growth as other hormonal treatments can.
LINK(S):
FDA news release (Free)
Published in Physician's First Watch December 30, 2008
Your Remark:
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.